<DOC>
	<DOCNO>NCT00121836</DOCNO>
	<brief_summary>This single-arm study design evaluate efficacy safety oral Xeloda plus intravenous Avastin first-line treatment woman metastatic breast cancer . Patients receive Xeloda 1000 mg/mÂ² orally ( PO ) twice daily ( BID ) Days 1-15 , Avastin 15 mg intravenously ( IV ) Day 1 3-week cycle . The anticipated time study treatment disease progression unacceptable toxicity . The target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Xeloda ( Capecitabine ) Women With HER2-Negative Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Women &gt; =18 year age HER2negative metastatic breast cancer Previous adjuvant chemotherapy hormonal treatment &gt; =1 measurable target lesion Previous treatment chemotherapy , antiangiogenic agent , biologic therapy advance metastatic cancer Radiation therapy within 4 week study treatment start insufficient recovery effect prior radiation therapy Central nervous system metastases Other malignancy within last 5 year , except cure basal cell carcinoma skin carcinoma situ uterine cervix Serious concurrent infection</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>